A case report and literature review on anakinra in the treatment of refractory adult onset Still’s disease
- VernacularTitle:阿那白滞素治疗1例难治性成人斯蒂尔病及文献复习
- Author:
Yumin YAN
1
;
Jie LIU
2
;
Xia ZHANG
3
;
Xue ZHONG
4
Author Information
1. Dept. of Pharmacy，Peking University People’s Hospital，Beijing 100044，China;Dept. of Clinical Pharmacy，Zhongshan People’s Hospital，Guangdong Zhongshan 528400，China
2. Dept. of Pharmacy，Peking University People’s Hospital，Beijing 100044，China;Dept. of Clinical Pharmacy，Affiliated Hospital of Jining Medical University，Shandong Jining 272000，China
3. Dept. of Rheumatology and Immunology，Peking University People’s Hospital，Beijing 100044，China
4. Dept. of Pharmacy，Peking University People’s Hospital，Beijing 100044，China
- Publication Type:Journal Article
- Keywords:
anakinra;
adult onset Still’s disease;
derma-
- From:
China Pharmacy
2025;36(19):2442-2447
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the efficacy and safety of the interleukin-1 （IL-1） receptor antagonist anakinra in the treatment of refractory adult onset Still’s disease （AOSD）， and provide more real-world evidence and practical experience for the treatment of AOSD with this drug. METHODS A retrospective analysis was conducted on the diagnosis and treatment process of a patient with AOSD complicated with dermatomyositis who received anakinra； systematically searched for relevant literature on the treatment of AOSD with anakinra in Chinese and English databases such as CNKI， PubMed， Medline， etc.， and conduct literature review on its efficacy and safety. RESULTS The patient in this case had poor treatment with multiple traditional drugs and was considered to have AOSD combined with dermatomyositis. After being admitted to the hospital and treated with a combination therapy of anakinra and glucocorticoids for several days， the patient’s clinical symptoms and inflammatory indicators significantly improved， and no serious adverse drug reactions occurred. Pharmacists designed specialized pharmaceutical monitoring pathways and conduct regular follow-up after discharge. After discharge， the patient took medication regularly， and the condition was maintained and relieved； during this period， there was redness and swelling at the injection site which resolved on its own without any other obvious discomfort. Literature review showed that anakinra could increase the response rate and remission rate of AOSD patients， and significantly reduce the dosage of glucocorticoids； adverse events were mainly injection site reactions， with a low overall risk of infection and good safety； however， there was a significant difference in the treatment course， and there was currently no unified plan. CONCLUSIONS Anakinra is an efficient and safe biological agent for treating AOSD， which can rapidly induce and maintain disease remission. For AOSD patients， clinical consideration may be given to using IL-1 antagonists to reduce glucocorticoid dependence， while strengthening long-term medication monitoring.
